Louisiana Medicaid Lidocaine Patch Kits

The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request clinical authorization for lidocaine patch kits (kits combining prescription lidocaine patches in the same package with another product).

Additional Point-of-Sale edits may apply.

Approval Criteria for Initial and Reauthorization Requests

- The recipient is 18 years of age or older; **AND**
- The recipient has a diagnosis of post-herpetic neuralgia; AND
- Previous use of preferred lidocaine patch **ONE** of the following is required:
 - O The recipient has had an *intolerable side effect* with an inactive ingredient in the preferred lidocaine patch that is not an ingredient in the requested lidocaine patch kit, and the ingredient is listed on the request; **OR**
 - The recipient has a *contraindication* to an inactive ingredient in the preferred lidocaine patch that is not an ingredient in the requested lidocaine patch kit, and the ingredient is listed on the request; **OR**
 - The request includes other *clinical justification* why the preferred lidocaine patch cannot be used: **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning(s), Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; AND
 - All laboratory testing and clinical monitoring parameters are completed as instructed in the prescribing information and will be repeated as recommended;
 AND
 - The recipient has no concomitant drug therapies or disease states that would limit the use of the requested medication and will not be receiving the requested medication in combination with any medication that is contraindicated or not recommended per FDA labeling.

Duration of initial and reauthorization approval: 3 months

References

Prilo Patch II (lidocaine and prilocaine, lidocaine) [package insert] Panorama City, CA: PureTek Corporation; February 2015

 $\frac{https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a97a3c99-66f6-2077-e053-2a95a90a1ce7\&type=display$

Revision / Date	Implementation Date
Policy created / March 2021	July 2021